Abstract | BACKGROUND: PATIENTS AND METHODS: Serum testosterone levels were measured prospectively in a cohort of patients given LHRHA for 6 months. End points were time to progression ( TTP) and overall survival (OS). RESULTS: The study population was 153 patients: 54 with metastatic disease and 99 with biochemical failure. In multivariate analysis, adjustment for age, baseline serum prostatic specific antigen (PSA) levels, Gleason score, and disease stage, testosterone levels < 50 ng/dL failed to be associated with TTP and OS. A cutoff of < 20 ng/dL was associated with a nonsignificant lower risk of progression (adjusted hazard ratio [HR] 0.58; 95% confidence interval [CI] 0.30-1.15; P = .12) and a significant lower risk of death (adjusted HR, 0.19; 95% CI, 0.04-0.76; P = .02). Only 25 patients attained serum testosterone levels < 20 ng/dL. Using a receiver operating characteristic curve (ROC), we found that a testosterone value of 30 ng/dL offered the best overall sensitivity and specificity for prediction of death. Serum testosterone levels < 30 ng/mL were associated with a significantly lower risk of death (adjusted HR, 0.45; 95% CI, 0.22-0.94; P = .034. CONCLUSIONS: Serum testosterone levels lower than the currently adopted cutoff of 50 ng/dL have a prognostic role in patients with prostate cancer receiving LHRHA and are a promising surrogate parameter of LHRHA efficacy.
|
Authors | Valentina Bertaglia, Marcello Tucci, Cristian Fiori, Emiliano Aroasio, Massimiliano Poggio, Consuelo Buttigliero, Susanna Grande, Andrea Saini, Francesco Porpiglia, Alfredo Berruti |
Journal | Clinical genitourinary cancer
(Clin Genitourin Cancer)
Vol. 11
Issue 3
Pg. 325-330.e1
(Sep 2013)
ISSN: 1938-0682 [Electronic] United States |
PMID | 23531429
(Publication Type: Journal Article)
|
Copyright | Copyright © 2013 Elsevier Inc. All rights reserved. |
Chemical References |
- Androgen Antagonists
- Antineoplastic Agents, Hormonal
- Biomarkers
- Gonadotropin-Releasing Hormone
- Testosterone
|
Topics |
- Aged
- Aged, 80 and over
- Androgen Antagonists
(therapeutic use)
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Biomarkers
(blood)
- Gonadotropin-Releasing Hormone
(analogs & derivatives)
- Humans
- Male
- Middle Aged
- Prospective Studies
- Prostatic Neoplasms
(blood, drug therapy, mortality)
- Survival
- Testosterone
(blood)
- Treatment Outcome
|